(NASDAQ: ELDN) Eledon Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 45.66%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.83%.
Eledon Pharmaceuticals's earnings in 2025 is -$75,576,000.On average, 9 Wall Street analysts forecast ELDN's earnings for 2025 to be -$38,878,026, with the lowest ELDN earnings forecast at -$41,113,497, and the highest ELDN earnings forecast at -$37,128,005. On average, 7 Wall Street analysts forecast ELDN's earnings for 2026 to be -$56,486,110, with the lowest ELDN earnings forecast at -$76,940,974, and the highest ELDN earnings forecast at -$45,308,752.
In 2027, ELDN is forecast to generate -$55,934,733 in earnings, with the lowest earnings forecast at -$60,495,575 and the highest earnings forecast at -$51,601,635.